Home » Mylan Shoots for Late 2013 Launch of Generic of Teva’s Copaxone
Mylan Shoots for Late 2013 Launch of Generic of Teva’s Copaxone
Despite analyst doubts, Mylan is confident it can launch a generic version of Teva’s blockbuster multiple sclerosis treatment Copaxone in the second half of 2013 pending FDA approval and resolution of legal challenges. Mylan expects a court decision “any day” on whether its ANDA impinges on Teva’s patents for the drug, CEO Heather Bresch said on a financial call.
Generic Line
Generic Line
Upcoming Events
-
07May
-
14May
-
30May